Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile?

Cancer

Volumn 117, Issue 13, 2011, Pages 2853-2862

  Kennedy, Erin D ^a,b,c,d,e   Schmocker, Selina ^b   Victor, Charles ^d   Baxter, Nancy N ^d,e,f,g   Kim, John ^c,e   Brierley, James ^c,e   McLeod, Robin S ^b,c,d,e  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

clinical policy; patient preferences; preoperative chemoradiation; rectal cancer; threshold technique

Indexed keywords

ADULT; ARTICLE; CANCER RECURRENCE; CHEMORADIOTHERAPY; EDUCATIONAL STATUS; FEMALE; FUNCTIONAL STATUS; HUMAN; INTERVIEW; MALE; NORMAL HUMAN; PATIENT ATTITUDE; PATIENT DECISION MAKING; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT PREFERENCE; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 79959608510     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25842     Document Type: Article

References (43)

1. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345: 638-646.
2. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007; 246: 693-701. (Pubitemid 350035641)
3. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch Colorectal Cancer Group study. J Clin Oncol. 2005; 23: 6199-6206.
4. Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005; 23: 1847-1858. (Pubitemid 46211362)
5. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 1731-1740.
6. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M., Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93: 1215-1223. (Pubitemid 44547018)
7. Pietrzak L, Bujko K, Nowacki MP, et al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial. Radiother Oncol. 2007; 84: 217-225. (Pubitemid 47362404)
8. Merkel S, Mansmann U, Siassi M, Papadopoulos T, Hohenberger W, Hermanek P., The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis. 2001; 16: 298-304. (Pubitemid 32927002)
9. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004; 22: 1785-1796. (Pubitemid 41095168)
10. Carne PW, Nelson H., Are we overtreating rectal cancer: time for another trial? Ann Surg Oncol. 2004; 11: 124-126. (Pubitemid 40486785)
11. Mamon H, Willett CG., Is radiation therapy required for patients with intermediate-risk rectal cancer? Clin Adv Hematol Oncol. 2007; 5: 638-644, 585.
12. Kachnic LA, Hong TS, Ryan DP., Rectal cancer at the crossroads: the dilemma of clinically staged T3, N0, M0 disease. J Clin Oncol. 2008; 26: 350-351. (Pubitemid 351171682)
13. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007; 243: 132-139.
14. Smith N, Brown G., Preoperative staging of rectal cancer. Acta Oncol. 2008; 47: 20-31.
15. Burton S, Brown G, Daniels IR, Norman AR, Mason B, Cunningham D., MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer. 2006; 94: 351-357. (Pubitemid 43237559)
16. Glynn-Jones R., Whose guidelines are they anyway? Clin Oncol (R Coll Radiol). 2010; 22: 261-264.
17. Kornmann M, Henne-Bruns D, Porzsolt F., Neoadjuvant treatment of rectal carcinoma: assessment of health care services by physicians and lay persons. J Clin Oncol. 2008; 26: 4866-4868.
18. Cedermark B, Johansson H, Rutqvist LE, Wilking N., The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer. 1995; 75: 2269-2275.
19. Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B., The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer. 2001; 92: 896-902. (Pubitemid 32783078)
20. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997; 336: 980-987.
21. Tjandra JJ, Kilkenny JW, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum. 2005; 48: 411-423.
22. Wong RK, Berry S, Spithoff K, et al. Preoperative or postoperative therapy for stage II or III rectal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 2010; 22: 265-271.
23. Ware JE Jr, Sherbourne CD., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
24. Stewart AL, Hays RD, Ware JE Jr., The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988; 26: 724-735.
25. Llewellyn-Thomas HA., Investigating patients' preferences for different treatment options. Can J Nurs Res. 1997; 29: 45-64. (Pubitemid 127473358)
26. Llewellyn-Thomas H, Thiel E, Paterson M, Naylor D., In the queue for coronary artery bypass grafting: patients' perceptions of risk and "maximal acceptable waiting time. " J Health Serv Res Policy. 1999; 4: 65-72. (Pubitemid 29186855)
27. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD., Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making. 1996; 16: 262-282.
28. Dales RE, O'Connor A, Hebert P, Sullivan K, McKim D, Llewellyn-Thomas H., Intubation and mechanical ventilation for COPD: development of an instrument to elicit patient preferences. Chest. 1999; 116: 792-800. (Pubitemid 29428501)
29. Kennedy ED, To T, Steinhart AH, Detsky A, Llewellyn-Thomas HA, McLeod RS., Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile? Inflamm Bowel Dis. 2008; 14: 224-235. (Pubitemid 351288044)
30. Palda VA, Llewellyn-Thomas HA, Mackenzie RG, Pritchard KI, Naylor CD., Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol. 1997; 15: 3192-3200. (Pubitemid 27419331)
31. Brundage MD, Davidson JR, Mackillop WJ., Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997; 15: 330-340. (Pubitemid 27020591)
32. Brundage MD, Davidson JR, Mackillop WJ, Feldman-Stewart D, Groome P., Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer. Med Decis Making. 1998; 18: 256-267. (Pubitemid 28307555)
33. Hendren SK, O'Connor BI, Liu M, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg. 2005; 242: 212-223. (Pubitemid 41033438)
34. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26: 191-208. (Pubitemid 30194541)
35. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A., The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49: 822-830. (Pubitemid 27246947)
36. Rosner B., Fundamentals of Biostatistics. 4th ed. Boston, MA: Duxbury Press; 1995.
37. McCullagh P., Regression models for ordinal data (with discussion). J R Stat Soc B. 1980; 42: 109-142.
38. Couture J, Chan R, Bouharaoui F., Patient's preferences for adjuvant postoperative chemoradiation therapy in rectal cancer. Dis Colon Rectum. 2005; 48: 2055-2060. (Pubitemid 43035111)
39. Harrison JD, Solomon MJ, Young JM, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg. 2008; 143: 389-394. (Pubitemid 351574858)
40. Solomon MJ, Pager CK, Keshava A, et al. What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer. Dis Colon Rectum. 2003; 46: 1351-1357. (Pubitemid 37267629)
41. Eddy DM., Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA. 1990; 263:3077, 3081, 3084.
42. Siminoff LA, Gordon NH, Silverman P, Budd T, Ravdin PM., A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology. 2006; 15: 1001-1013. (Pubitemid 44762705)
43. Peele PB, Siminoff LA, Xu Y, Ravdin PM., Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making. 2005; 25: 301-307. (Pubitemid 40696279)